GSK plc (NYSE:GSK) is considered one of the best undervalued European stocks to buy now, with fourth-quarter earnings exceeding analyst expectations. Earnings per share were $0.6989, 9.58% higher than the forecast, while revenue reached $11.81 billion, a 3.96% upside surprise. Specialty Medicines and Oncology showed strong growth.

The company issued positive guidance for 2026, projecting 3-5% sales growth and 7-9% core operating profit and earnings per share growth. GSK management highlighted oncology, respiratory medicines, and an expanding pipeline as key drivers of future growth. GSK is a UK-based biopharmaceutical company focusing on medicines and vaccines for various diseases.

While GSK shows investment potential, certain AI stocks offer higher upside with less risk. For those seeking an undervalued AI stock benefiting from Trump-era tariffs, a free report on the best short-term AI stock is available. Check out 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds for more insights.

Read more at Yahoo Finance: GSK plc (GSK) Q4 Results Topped Forecasts as Specialty Medicines Jump 17%